Ann: PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour Size, page-81

Yes you are right, the more cutting edge the science the more risk. It's all about risk and return. As a long-term holder, I am willing to take the risk because I choose to believe in the top-notch Yale researchers, well known experts of Scientific Advisory Board, and highly qualified management team with proven track record.

For investors with risk averse mentality, the best way to avoid the risk is don't buy in until a deal is inked. Big Pharma companies have their technical experts to conduct rigorous Due Diligence for sure, so no worries.